Bolt Biotherapeutics (BOLT) News Today $5.60 -0.19 (-3.28%) Closing price 06/23/2025 04:00 PM EasternExtended Trading$5.68 +0.08 (+1.34%) As of 08:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipShort InterestTrendsBuy This Stock BOLT Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Citadel Advisors LLC Takes Position in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT)Citadel Advisors LLC bought a new position in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 78,961 shares of the company's stock, valued at approximately $42,000. CitJune 12, 2025 | marketbeat.comShort Interest in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Decreases By 91.6%Bolt Biotherapeutics, Inc. (NASDAQ:BOLT - Get Free Report) was the target of a large drop in short interest in the month of May. As of May 31st, there was short interest totalling 21,500 shares, a drop of 91.6% from the May 15th total of 256,500 shares. Approximately 1.7% of the company's stock are short sold. Based on an average daily volume of 18,900 shares, the short-interest ratio is currently 1.1 days.June 11, 2025 | marketbeat.comSquarepoint Ops LLC Buys New Holdings in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT)Squarepoint Ops LLC purchased a new stake in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 48,971 shares of the company's stock, valued at apJune 11, 2025 | marketbeat.comBolt Biotherapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 12, 2025 | globenewswire.comBolt Biotherapeutics to Host KOL Conference Call and Webcast to Discuss BDC-3042 Phase 1 Results and Corporate UpdatesMay 8, 2025 | globenewswire.comBolt Biotherapeutics Presents Preclinical Results for Next-Generation Boltbody™ ISACs targeting CEA and PD-L1 at AACR Annual Meeting 2025April 30, 2025 | globenewswire.comBolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025April 25, 2025 | globenewswire.comBolt Biotherapeutics reports Q4 EPS (42c), consensus (35c)March 27, 2025 | markets.businessinsider.comBolt Biotherapeutics, Inc.: Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business UpdateMarch 26, 2025 | finanznachrichten.deBolt Biotherapeutics Updates on Clinical Trials and Financial Results, Anticipates Milestones for BDC-4182 and BDC-3042March 26, 2025 | nasdaq.comBolt Biotherapeutics price target lowered to $1.25 from $1.50 at StifelMarch 26, 2025 | markets.businessinsider.comBolt Biotherapeutics to Present Data from Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025March 25, 2025 | globenewswire.comBolt Biotherapeutics Reports 2024 Financial Results and UpdatesMarch 25, 2025 | tipranks.comBolt Biotherapeutics Inc.: Q4 Earnings SnapshotMarch 24, 2025 | sfgate.comBolt Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business UpdateMarch 24, 2025 | globenewswire.comBolt Technology Reportedly Exploring IPO for Ride-Hailing OperationFebruary 26, 2025 | pymnts.comBolt Biotherapeutics to Participate in Upcoming March ConferencesFebruary 25, 2025 | globenewswire.comBolt Biotherapeutics and Toray Industries Collaborate on Immunotherapy Targeting Novel Cancer Antigen Caprin-1 for Solid TumorsFebruary 13, 2025 | nasdaq.comBolt Biotherapeutics provides update on co-development collaboration with TorayFebruary 11, 2025 | markets.businessinsider.comBolt Biotherapeutics, Inc. Provides Update on Global Cancer Immunotherapy Co-Development with Toray Industries, Inc.February 11, 2025 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM), Nurix Therapeutics (NRIX) and Merit Medical Systems (MMSI)January 29, 2025 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Exelixis (EXEL) and Vertex Pharmaceuticals (VRTX)January 13, 2025 | markets.businessinsider.comBolt Biotherapeutics Third Quarter 2024 Earnings: Misses ExpectationsNovember 15, 2024 | finance.yahoo.comBolt Biotherapeutics Reports Q3 2024 Financial ResultsNovember 15, 2024 | markets.businessinsider.comBolt Biotherapeutics’ Restructuring Faces Potential Setbacks: A Closer LookNovember 15, 2024 | markets.businessinsider.comBolt Biotherapeutics, Inc. (BOLT) Reports Q3 Loss, Tops Revenue EstimatesNovember 13, 2024 | msn.comBolt Biotherapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 13, 2024 | markets.businessinsider.comBolt Biotherapeutics Presents Updated Preclinical Data for BDC-4182 and Key Learnings from Phase 1 Dose-Escalation Trial of BDC-1001 at SITC 39th Annual MeetingNovember 7, 2024 | globenewswire.comBy popular demand, Epiphone brings back the Mike Dirnt and Gene Simmons-approved Grabber BassSeptember 27, 2024 | msn.comOncology Institute (NASDAQ:TOI) Stock Quotes, Forecast and News SummarySeptember 23, 2024 | benzinga.comBolt Biotherapeutics Announces Changes to its Board of DirectorsSeptember 4, 2024 | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Bolt Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - BOLTSeptember 3, 2024 | prnewswire.comBOLT Investors Have the Opportunity to Lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law FirmSeptember 3, 2024 | prnewswire.comBOLT Deadline: Rosen Law Firm Urges Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) Stockholders with Large Losses to Contact the Firm for Information About Their RightsSeptember 2, 2024 | businesswire.comBOLT Investors Have the Opportunity to Lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law FirmSeptember 2, 2024 | globenewswire.comINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of BoltAugust 31, 2024 | prnewswire.comBOLT Deadline: BOLT Investors Have Opportunity to lead Bolt Biotherapeutics, Inc. Securities Fraud LawsuitAugust 30, 2024 | prnewswire.comBOLT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Bolt Biotherapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!August 30, 2024 | globenewswire.comDEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of BoltAugust 29, 2024 | globenewswire.comBolt Biotherapeutics to Participate in Upcoming September ConferencesAugust 28, 2024 | finance.yahoo.comBOLT FINAL DEADLINE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Bolt Biotherapeutics, Inc. Investors to Secure Counsel Before Important September 3 Deadline in Securities Class Action – BOLTAugust 28, 2024 | globenewswire.comBOLT Investors Have the Opportunity to Lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law FirmAugust 27, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Bolt Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - BOLTAugust 26, 2024 | prnewswire.comA Case Is Being Pursued Against Bolt Biotherapeutics Inc For Securities Law Violations And The Schall Law Firm Urges Investors To Take PartAugust 25, 2024 | stockhouse.comBOLT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Bolt Biotherapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!August 25, 2024 | globenewswire.comROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Bolt Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – BOLTAugust 24, 2024 | globenewswire.comBOLT Investors Have Opportunity to lead Bolt Biotherapeutics, Inc. Securities Fraud LawsuitAugust 23, 2024 | prnewswire.comBOLT Investors Have the Opportunity to Lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law FirmAugust 22, 2024 | prnewswire.comROSEN, LEADING TRIAL ATTORNEYS, Encourages Bolt Biotherapeutics, Inc. Investors to Secure Counsel Before Important September 3 Deadline in Securities Class Action – BOLTAugust 21, 2024 | globenewswire.comINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of BoltAugust 21, 2024 | prnewswire.com Get Bolt Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BOLT and its competitors with MarketBeat's FREE daily newsletter. Email Address BOLT Media Mentions By Week BOLT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BOLT News Sentiment▼0.000.62▲Average Medical News Sentiment BOLT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BOLT Articles This Week▼02▲BOLT Articles Average Week Get Bolt Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BOLT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Curis News SAB Biotherapeutics News Molecular Templates News Amgen News Gilead Sciences News Vertex Pharmaceuticals News Regeneron Pharmaceuticals News Alnylam Pharmaceuticals News Biogen News Incyte News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BOLT) was last updated on 6/24/2025 by MarketBeat.com Staff From Our Partners12 “perfect” stocksJoin the Dream Team and see how we can guarantee stock market wins Credentials are a good thing, especiall...Zacks | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s true trade war strategyThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | SponsoredIs Tesla a buy right now?Wall Street Legend: Why stocks are very likely to crash in Trump's 2nd Year Legendary investor Marc Chaikin...Chaikin Analytics | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWall Street is using Bitcoin against youBitcoin is rising again, and institutions are pouring billions into Bitcoin ETFs. At first glance, that mig...Brownstone Research | SponsoredWhy Is President Trump Fast-Tracking These Companies?Forget about AI… There's a hot new trend on Wall Street… and it's all thanks to President Trump. His administr...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bolt Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bolt Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy BOLT Stock Free BOLT Stock Alerts